Laurion Capital Management LP cut its stake in shares of Clementia Pharmaceuticals Inc (NASDAQ:CMTA) by 11.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 202,697 shares of the company’s stock after selling 26,057 shares during the period. Laurion Capital Management LP owned approximately 0.64% of Clementia Pharmaceuticals worth $2,667,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Clementia Pharmaceuticals by 5.5% during the first quarter. JPMorgan Chase & Co. now owns 744,869 shares of the company’s stock worth $11,285,000 after purchasing an additional 38,572 shares during the period. Artal Group S.A. acquired a new position in Clementia Pharmaceuticals during the first quarter valued at $3,030,000. Sphera Funds Management LTD. raised its position in Clementia Pharmaceuticals by 22.7% during the first quarter. Sphera Funds Management LTD. now owns 200,000 shares of the company’s stock valued at $3,030,000 after buying an additional 37,000 shares during the period. DAFNA Capital Management LLC raised its position in Clementia Pharmaceuticals by 75.0% during the first quarter. DAFNA Capital Management LLC now owns 105,000 shares of the company’s stock valued at $1,591,000 after buying an additional 45,000 shares during the period. Finally, Birchview Capital LP raised its position in Clementia Pharmaceuticals by 78.9% during the second quarter. Birchview Capital LP now owns 68,000 shares of the company’s stock valued at $895,000 after buying an additional 30,000 shares during the period. 72.13% of the stock is currently owned by institutional investors.
NASDAQ:CMTA opened at $10.24 on Monday. The firm has a market cap of $324.79 million and a P/E ratio of -1.29. Clementia Pharmaceuticals Inc has a 1-year low of $8.10 and a 1-year high of $20.15.
Clementia Pharmaceuticals (NASDAQ:CMTA) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.09. equities analysts predict that Clementia Pharmaceuticals Inc will post -1.56 EPS for the current fiscal year.
CMTA has been the topic of several recent analyst reports. Zacks Investment Research raised Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 13th. B. Riley dropped their price target on Clementia Pharmaceuticals from $25.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, August 15th. Morgan Stanley dropped their price target on Clementia Pharmaceuticals from $27.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday, August 13th. Finally, Wedbush reissued an “outperform” rating and set a $26.00 price target on shares of Clementia Pharmaceuticals in a research report on Friday, August 10th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $22.67.
Clementia Pharmaceuticals Profile
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
Want to see what other hedge funds are holding CMTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clementia Pharmaceuticals Inc (NASDAQ:CMTA).
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.